Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.
about
Self-association of human PCSK9 correlates with its LDLR-degrading activityHepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberineNew developments in atherosclerosis: clinical potential of PCSK9 inhibitionProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesEvaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancerAntagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 CellsA proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesPCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signalingIDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaProprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterolInhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathwayMolecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).A cholesterol-lowering VLP vaccine that targets PCSK9Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamstersEffects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Effects of elaidic acid on lipid metabolism in HepG2 cells, investigated by an integrated approach of lipidomics, transcriptomics and proteomics.Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytesHepatocytes respond differently to major dietary trans fatty acid isomers, elaidic acid and trans-vaccenic acid.Common and rare gene variants affecting plasma LDL cholesterolPlasma PCSK9 levels are significantly modified by statins and fibrates in humansPCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.Inflammation stimulates the expression of PCSK9Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9.PCSK9: a convertase that coordinates LDL catabolism.Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic miceLysine acetylation in the lumen of the ER: a novel and essential function under the control of the UPR.Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases.The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells.PCSK9 inhibition: current concepts and lessons from human genetics.
P2860
Q24306591-01C5C3BD-36E9-4EAE-B3EE-D2A6454947B8Q24652495-5987328B-E5A3-499C-B848-75F47862EDBEQ26783407-F355DA20-A3AB-4134-9432-2141568FEB95Q27009477-80BFD4B0-2F15-4D6C-A7DD-866B9F024D38Q27026358-D333B95C-8544-4812-9EC4-C0030239AC06Q27653836-0BAF779D-AFA1-40C5-B1B4-96F338D1B3F1Q27655476-02C9AF22-D4AA-4CCA-8FA9-C7EA36D61E1BQ28586625-35981188-679E-46C4-9917-E48815249130Q30538763-20123A21-D1E9-457A-88F6-C13E5228E639Q33577851-AD9F7DDD-FC7A-4AD1-8C94-179B6CC580CFQ33728343-A3029ABF-240E-4D70-88CF-44160A6A7BEFQ33970677-6FBEFA48-6464-49B8-BB6E-443695F32BFBQ34053143-9937669B-8B95-4A92-990E-36C8E324D182Q34455663-99F7489E-043C-492A-9680-E38BDF5512D3Q34458693-3FE1B637-BFFB-447F-BBD1-C0A0AE9F0B46Q34496015-03396D85-BC49-435B-ADB1-DBA1C212CEBAQ34559944-FEC75F56-CF29-4532-8CD7-ABEB77E49385Q34662589-559F3DFB-8270-4524-9523-763A4F5B86A6Q34994595-7F4FEFB0-10B4-4B37-A5F6-E34362DE76DAQ35217031-6EC8F9D1-1466-4D70-88F4-94334B9B6AEEQ36020286-DE5DE552-5264-4C05-9D52-0F33634FABC2Q36336243-F1FEB907-14DB-4858-BAD6-05BA80FF79A7Q36711327-500BD0CA-AFA9-4E2C-90EF-EF51A3170123Q36728777-56CD7AC3-61C6-4517-AFEA-B97FF1FFFEC7Q36862604-FB852095-6F24-483D-AFCB-F62F9B6E4458Q36866980-AB417085-35D3-4D7B-859C-9F24AC94D3F7Q36945328-E3A21D3B-C1EC-4165-9162-34A4D93AF241Q37116362-6EEC739C-FCCC-409A-AA48-4599503BB220Q37173223-28F4892C-B726-452A-85B3-CCA276ADA4B8Q37297854-057BF504-8938-42A9-A44B-FBD42F6C0E4BQ38068055-BE44207D-6A58-4101-9F75-BFE4423F1DA4Q38078264-E01E6559-64A8-4687-B3F5-3A6CCBDFDB55Q38098501-38A9F6D4-D6EF-4AD3-8A8A-EDAD809AE878Q38110701-6FEE33E3-19AB-40DB-8488-60A286219542Q38124404-9D81BC12-227F-4790-8248-4797E7A90330Q38217797-9BE10A84-1C1F-4B69-A456-FEE0636AA0F6Q38268342-26EB6921-DC37-4FA4-9E6B-701249539BC6Q38299279-1431359B-36D1-477A-842F-435E2B95139CQ38328173-AF7AF348-CE0F-4736-996A-5CD03009DF08Q38338236-35F08DF6-B7AB-4650-A73D-158FF990FBBC
P2860
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Secreted PCSK9 downregulates l ...... receptor-mediated endocytosis.
@en
type
label
Secreted PCSK9 downregulates l ...... receptor-mediated endocytosis.
@en
prefLabel
Secreted PCSK9 downregulates l ...... receptor-mediated endocytosis.
@en
P2093
P2860
P1476
Secreted PCSK9 downregulates l ...... receptor-mediated endocytosis.
@en
P2093
David E Moller
Guoqing Cao
Mariam E Ehsani
Patrick I Eacho
Robert J Konrad
Robert J Schmidt
Shaoyou Chu
P2860
P304
P356
10.1194/JLR.M700071-JLR200
P577
2007-04-20T00:00:00Z